Simpson Thacher Represents Underwriters in $3 Billion Debt Offering by AstraZeneca
08.21.18
This is only gets display when printing
Simpson Thacher represented the underwriters in the U.S. registered public offering by AstraZeneca PLC of $3 billion of Senior Notes with maturities ranging between five and thirty years. The offering closed on August 17, 2018, with the net proceeds being used for general corporate purposes, which may include the refinancing of existing indebtedness.
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca is headquartered in the United Kingdom and its American Depositary Shares are listed on the New York Stock Exchange under the symbol “AZN.”
The Simpson Thacher team included Joseph Kaufman, Mark Brod, John O’Connell, Niyati Roy and John Loubriel (Capital Markets); Jonathan Cantor and Christopher Murray (Tax); Abram Ellis (Regulatory and Compliance); and Jennie Getsin (FINRA and Blue Sky). Associates Atsushi Usui and Summer Associate Tarra Theisen provided valuable assistance.